Naperville, IL -- (SBWIRE) -- 10/17/2014 -- Reportstack, provider of premium market research reports announces the addition of Asthma - Pipeline Review, H2 2014 market report to its offering
Asthma - Pipeline Review, H2 2014
Asthma - Pipeline Review, H2 2014, provides an overview of the Asthmas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.
report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Asthma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Asthma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Asthma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Asthma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Biotec Pharmacon ASA
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Nissan Chemical Industries, Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Vectura Group plc
Hanwha Chemical Co., Ltd.
Astellas Pharma Inc.
Chiesi Farmaceutici SpA
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Laboratoires Pierre Fabre SA
Mitsubishi Tanabe Pharma Corporation
Ono Pharmaceutical Co., Ltd.
SK Chemicals Co., Ltd.
Teva Pharmaceutical Industries Limited
Zambon Company S.p.A.
OPKO Health, Inc.
iCo Therapeutics Inc.
Antisense Therapeutics Limited
Basilea Pharmaceutica AG
Orchid Chemicals & Pharmaceuticals Ltd
Palatin Technologies, Inc.
Yungjin Pharm Ind. Co., Ltd.
WhanIn Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Dynavax Technologies Corporation
Ahn-Gook Pharmaceutical Co., Ltd.
Verona Pharma Plc
Alba Therapeutics Corporation
Farmacija d.o.o. Tuzla
Hutchison MediPharma Limited
Aquinox Pharmaceuticals Inc.
Circassia Holdings Ltd.
Nostrum Pharmaceuticals, LLC
Axikin Pharmaceuticals, Inc.
MSM Protein Technologies, Inc.
Hydra Biosciences, Inc.
Theraclone Sciences, Inc.
Monosol Rx, LLC
Sparsha Pharma International Pvt. Ltd.
Vitae Pharmaceuticals, Inc.
Adamis Pharmaceuticals Corporation
ISU ABXIS Co.,Ltd.
KAEL-GemVax Co., Ltd.
Afferent Pharmaceuticals, Inc.
LegoChem Biosciences, Inc
Trimel BioPharma SRL
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Fountain Biopharma Inc.
Spring Bank Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
Corridor Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc.
NeoPharm Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Lead Discovery Center GmbH
Griffin Discoveries BV
High Point Pharmaceuticals, LLC
Visionary Pharmaceuticals, Inc.
Qu Biologics Inc.
Incozen Therapeutics Pvt Ltd
sterna biologicals Gmbh & Co KG
Rhizen Pharmaceuticals SA
ARA Healthcare Pvt. Ltd.
Panmira Pharmaceuticals, LLC.
ReveraGen BioPharma, Inc.
Foresee Pharmaceuticals, LLC
Ziarco Pharma Ltd
Cellular Biomedicine Group, Inc.
INOXIA Lifesciences GmbH
Complete report is available